胸腺肽α1联合舒利迭预防COPD急性发作的临床研究  

Research on thymosinα1 combined with seretide in preventing acute exacerbation of chronic obstructive pulmonary disease

作　　者：乔卓妮 马利[1] 卢正斌 

机构地区：[1]佳县人民医院内科,陕西佳县719200

出　　处：《临床肺科杂志》2012年第10期1821-1822,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨胸腺肽α1联合舒利迭对COPD急性发作的预防作用。方法将120例COPD稳定期患者随机分为对照组与观察组,给予58例对照组患者常规治疗及舒利迭吸入,观察组患者在常规治疗及舒利迭吸入基础上给予胸腺肽α1皮下注射。随访1年,比较两组临床疗效、1年内急性发作情况及治疗前后肺功能改变。结果观察组与对照组治疗总有效率为87.0%和60.3%,观察组显著优于对照组(P=0.001);随访1年中,观察组急性发作次数、再发间隔时间及急性发作时间均显著少于对照组(P<0.05);两组治疗后肺功能FEV1、FEV1/FVC及FEV1/预计值均有所改善,P>0.05。结论胸腺肽α1联合舒利迭可有效预防COPD急性加重,效果优于单用舒利迭。Objective To explore the preventive effect of thymosincd on acute exacerbation of chronic obstructive pulmonary dis- ease （AECOPD）. Methods 120 cases with COPD were randomly divided into control group and observation group. 58 cases of control group were given routine treatment and seretide inhalation. 62 cases of observation group received thymosinal hypodermic injection based on the treatment of control group. The follow up lasted for 1 year. Clinical effect, the acute episode of disease and lung function were com- pared between two groups. Results The effective rate in experience group was much higher than that in control group with significant difference （P 〈0. 05 ） ; Time of acute attack, the mean interval between 2 episodes and acute attack duration in experience group greatly decreased compared with control group （P 〈 0, 05 ） ; FEVl , FEV1/FVC and FEVI/PV in two groups both improved after treatment, but there were no significant difference between two groups （ P 〉 0. 05 ）. Conclusions Compared with seretide single treatment, thymosinctl compare with seretide for preventing acute exacerbation of chronic obstructive pulmonary disease have better effect.

关 键 词：慢性阻塞性肺疾病 胸腺肽Α1 舒利迭 

分 类 号：R563.9[医药卫生—呼吸系统]